Immune Reconstitution

Phase I trial of CYT 99 007 initiated

Published in AIDS Weekly, February 9th, 2004

After U.S. Food and Drug Administration (FDA) approval of its investigational new drug (IND) application, Cytheris announced the entry of its first recombinant protein in a phase I clinical study.

CYT 99 007 is a recombinant human Interleukin-7 developed by Cytheris. This cytokine targets the immune reconstitution of immuno-compromised patients, undergoing cancer treatment, affected by AIDS, or recovering from a bone marrow transplant.

This first phase I is performed in Bethesda, Maryland, in cooperation with National Cancer Institute investigators. The clinical trial, including oncology patients, will evaluate the safety, the immune effects, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry